Drugs / PEG-interleukin-2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT00004695 | Sep 1997 → Mar 2000 | common variable immunodeficiency | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEG-interleukin-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004695 ↗ |
| Known as | PEG-IL-2 | “Determine whether polyethylene-glycol-conjugated interleukin 2 (PEG-IL-2) can reduce the number of infections in patients with common variable immunodeficiency.” NCT00004695 ↗ |
| Route | Subcutaneous | “Patients receive PEG-IL-2 or placebo by subcutaneous injection weekly for 18 months.” NCT00004695 ↗ |